Introduction: The Urgency of Now

The recent release of the FDA's "Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers (Revision 1, October 2025)" is more than just a regulatory update; it is a critical milestone in formalizing the landscape of compassionate use. For the patients we serve at Wondrlink, those facing terminal or life-threatening illnesses with no comparable alternatives, time is not measured in quarters or fiscal years-it is measured in days and moments.

This revised guidance offers much-needed clarity on the procedural complexities of Expanded Access (EA), transforming the opaque, case-by-case nature of the past into a framework defined by clear pathways and heightened sponsor accountability. Our mission at Wondrlink has always been to bridge the gap between breakthrough science and the patients who need it most. This guidance provides the regulatory foundation we need to accelerate that work, particularly in two key areas: procedural clarity and unprecedented transparency.

I. Interpreting the Mandate for Procedural Clarity

The FDA’s document reaffirms the three primary pathways for treatment use, but significantly refines the operational expectations for each. This clarity directly addresses the physician hesitation and institutional confusion that often stalls critical access decisions.

A. The Three Defined Pathways

The guidance re-establishes the distinctions between the three pathways, ensuring physicians and sponsors can quickly identify the appropriate route:

1. Individual Patient Access (Including Emergency Use): This remains the fastest pathway. The FDA’s commitment to a median turnaround of under one day for emergency requests is a testament to the Agency’s compassion. Crucially, the guidance provides a reminder that the physician must determine the probable risk from the drug is not greater than the probable risk from the disease—a high-stakes clinical judgment that requires clear, accessible data.
2. Intermediate-Size Patient Populations: For groups of patients who meet similar criteria, this pathway allows sponsors to consolidate requests under a single protocol, easing administrative burden for both the drug developer and the treating sites.
3. Treatment IND or Protocol: This pathway is reserved for widespread use, often bridging the gap between clinical trials and marketing approval. It signifies a stage where enough data exists to justify a broad rollout while remaining under an IND.

B. IRB Review and Informed Consent

The guidance clarifies the role of the Institutional Review Board (IRB), particularly in emergency situations. For individual emergency use, treatment may begin before a written IND is submitted, with the physician obtaining informed consent prior to administration. This protocol requires a written submission within 15 working days and IRB notification within five working days.

Furthermore, the inclusion of a standardized Informed Consent template (as referenced in the guidance) is a game-changer. It provides a blueprint for ensuring patients receive consistent, plain-language information about the investigational nature of the drug, the risks, and the benefits-a vital step in building patient trust.

II. The Cornerstone of Trust: Cures Act Transparency

Perhaps the most impactful section of the revised guidance centers on the transparency requirements mandated by the 21st Century Cures Act. The FDA has solidified the timeline and expectation for sponsor policy posting, marking a formal shift from optional access to mandated transparency.

Key Transparency Obligations for Sponsors:

Obligation

Requirement Defined in Guidance

Implications for Access

Public Policy Posting

Manufacturers and distributors must make their EA policies publicly available (e.g., on their website or other public platform).

Ends the era of private, inaccessible policies. The burden of discovery shifts away from the desperate patient.

Mandated Timing

Policies must be posted by the earlier of: 1) The first initiation of a Phase 2 or Phase 3 study, OR 2) Within 15 days after the drug receives a Fast Track, Breakthrough, or Regenerative Medicine Advanced Therapy designation.

This early timing ensures that the EA pathway is known to the patient population most likely to need it, often before full enrollment in trials is complete.

Policy Content

The policy must clearly describe how requests are evaluated, the process for communication with the requesting physician, and contact information.

This sets a standard for clear, navigable, and predictable responses, allowing physicians and patients to know exactly where they stand.

The guidance explicitly states that public posting will not be viewed as pre-approval promotion, provided the policy is not promotional in nature. This regulatory relief is essential for encouraging transparency without fear of compliance repercussions.

III. Bridging the Gap: From Guidance to Wondrlink’s Operational Solution

The FDA guidance provides the what and the why of expanded access transparency; Wondrlink provides the how. Our platform is specifically designed to operationalize this guidance, turning  regulatory compliance into actionable patient pathways.

For a physician facing a critically ill patient, navigating 100 different company websites to find 100 different policies is not feasible. For a drug sponsor, tracking and updating compliance across multiple development programs is a logistical nightmare. This is where the Wondrlink ecosystem provides the solution:

• For the Physician: Wondrlink's patient-centric platform acts as a centralized Resource Navigation Hub, leveraging the mandatory public policies to quickly identify investigational options, streamlining the matching process, and supporting the completion of necessary documentation (like Form FDA 3926).
• For the Sponsor: We help sponsors achieve and maintain compliance by providing a clear channel for their posted policies and by serving as a pre-screening layer that routes only relevant and qualified requests—protecting the integrity of ongoing clinical trials (a key FDA criterion) while ensuring compassionate access requests are handled efficiently and ethically.
• For the Patient (Wondrlink Foundation): Our Foundation provides the necessary education, awareness, and plain-language guides to empower patients to understand the serious risks and potential benefits articulated in the FDA’s new informed consent recommendations. We translate regulatory language into hope.

The future of Expanded Access is not about fighting the FDA; it's about leveraging the clarity they have provided.

Conclusion: A Shared Responsibility

The FDA's 2025 Revised Guidance is a regulatory opportunity to the EA community, offering the structural clarity needed to scale compassionate access. It places the onus of initial transparency squarely on the shoulders of the sponsors, requiring them to proactively inform the world about their process.

We must embrace this shared responsibility. Drug developers must move swiftly to ensure their policies are compliant, accessible, and robust. Physicians must utilize the streamlined forms and clearer pathways. And patient advocates must continue to demand that the letter of this guidance be met with the spirit of compassion.

At Wondrlink, we stand ready to partner with every stakeholder to translate this guidance into real-world action, ensuring that no patient is ever told "there's nothing left" simply because a regulatory pathway was too complex to navigate.

Let's use this guidance as a catalyst to unlock the therapies of the future, today.

The Wondrlink platform connects patients, physicians, and drug developers to accelerate access to investigational therapies for serious and life-threatening conditions.

Reference: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expanded-access-investigational-drugs-treatment-use-questions-and-answers-0